BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11307781)

  • 1. [Characteristics of a statine of the most recent generation].
    Notarbartolo A; Barbagallo CM
    Ital Heart J Suppl; 2001 Mar; 2(3):230-4. PubMed ID: 11307781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerivastatin.
    Cheng-Lai A
    Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety profile of statins].
    Prieto JC
    Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Schmitz-Madry A; Ugocsai P
    Curr Opin Lipidol; 2007 Apr; 18(2):164-73. PubMed ID: 17353665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical trials with rosuvastatin: efficacy and safety of its use].
    Schweiger C
    Ital Heart J; 2003 Dec; 4 Suppl 7():33S-46S. PubMed ID: 14983745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.